Drug safety testing paradigm, current progress and future challenges: An overview

Journal of Applied Toxicology

Volumn 34, Issue 6, 2014, Pages 576-594

  Ahuja, Varun ^a   Sharma, Sharad ^a  

^a LUPIN LIMITED   (India)

Author keywords

Biomarker; Drug safety; In vitro; Omics; Toxicity

Indexed keywords

ENDOCRINE DISRUPTOR; GALACTOSE; GLUCOSE; BIOLOGICAL MARKER;

ANIMAL MODEL; BIOMICS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CHOLESTASIS; COMPUTER MODEL; CYTOTOXICITY TEST; DRUG DESIGN; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; EMBRYO DEVELOPMENT; FERTILITY; GENETIC TOXICOLOGY; GENOTOXICITY; HEPG2 CELL LINE; HUMAN; IMAGING; IN VITRO STUDY; LIPIDOSIS; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MOLECULAR MODEL; NONHUMAN; PARAMETERS; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW; STEATOSIS; STEM CELL; TOXICOGENOMICS; TOXICOLOGY; TRANSLATIONAL RESEARCH; ANIMAL; ANIMAL TESTING ALTERNATIVE; CELL CULTURE; COOPERATION; FORECASTING; INTERDISCIPLINARY COMMUNICATION; PATIENT SAFETY; PROCEDURES; RISK ASSESSMENT; TOXICOGENETICS; TRENDS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; COOPERATIVE BEHAVIOR; FORECASTING; HUMANS; INTERDISCIPLINARY COMMUNICATION; MODELS, ANIMAL; PATIENT SAFETY; RISK ASSESSMENT; TOXICOGENETICS; TOXICOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84899619208     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2935     Document Type: Review

References (240)

1. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ. 2008. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 13: 527-537.
2. Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L, Gallagher WM, Callanan JJ, Suter L, Fountoulakis MM, Dekant W, Mally A. 2010. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol. Lett. 196: 1-11.
3. Afshari CA, Hamadeh HK, Bushel PR. 2011. The evolution of bioinformatics in toxicology: advancing toxicogenomics. Toxicol. Sci. 120(S1): S225-S237.
4. Ahmad ST, Arjumand W, Nafees S, Seth A, Ali N, Rashid S, Sultana S. 2012. Hesperidin alleviates acetaminophen induced toxicity in wistar rats by abrogation of oxidative stress, apoptosis and inflammation. Toxicol. Lett. 208: 149-161.
5. Amacher DE, Martin BA. 1997. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam. Appl. Toxicol. 40: 256-263.
6. Amacher DE. 2005. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12: 1829-1839.
7. Amacher DE. 2010. The discovery and development of proteomic safety biomarkers for the detection of drug induced liver toxicity. Toxicol. Appl. Pharmacol. 245: 134-142.
8. Astashkina A, Mann B, Grainger DW. 2012. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Therap. 134: 82-106.
9. Badea CT, Drangova M, Holdsworth DW, Johnson GA. 2008. In vivo small-animal imaging using micro-CT and digital subtraction angiography. Phys. Med. Biol. 53: R319-R350.
10. Baldrick P. 2008a. Safety evaluation to support first-in-man investigations I: Kinetic and Safety Pharmacology studies. Regul. Toxicol. Pharmacol. 51: 230-236.
11. Baldrick P. 2008b. Safety evaluation to support first-in-man investigations II: Toxicology studies. Regul. Toxicol. Pharmacol. 51: 237-243.
12. Bass AS, Cartwright ME, Mahon C, Morrison R, Snyder R, McNamara P, Bradley P, Zhou YY, Hunter J. 2009. Exploratory drug safety: A discovery strategy to reduce attrition in development. J. Pharmacol. Toxicol. Methods 60: 69-78.
13. Beger RD, Sun J, Schnackenberg LK. 2010. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243: 154-166.
14. Benbow JW, Aubrecht J, Banker MJ, Nettleton D, Aleo MD. 2010. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. Toxicol. Lett. 197: 175-182.
15. Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, Golder Z, Richards FM, Kimber G, Roach A, Alderton W, Fleming A. 2008. Zebrafish based assays for the assessment of cardiac, visual and gut function-potential safety screens for early drug discovery. J. Pharmacol. Toxicol. Methods 58: 59-68.
16. Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D. 1998. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114: 764-774.
17. Bérubé K, Prytherch Z, Job C, Hughes T. 2010. Human primary bronchial lung cell constructs: the new respiratory models. Toxicology 278: 311-318.
18. Beyoǧlu D, Idle JR. 2013. Metabolomics and its potential in drug development. Biochem. Pharmacol. 85: 12-20.
19. Biomarker Qualification Program FDA [WWW document]. URL http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm 284076.htm [accessed on 5 June 2013].
20. Blagg J. 2006. Structure-activity relationships for in vitro and in vivo toxicity. Annu. Rep. Med. Chem. 41: 353-368.
21. Blomme EA, Yang Y, Waring JF. 2009. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 186: 22-31.
22. +/_ mouse: modeling the mitochondrial role in drug toxicity. Drug Discov. Today 13: 982-988.
23. Breier JM, Gassmann K, Kayser R, Stegeman H, De Groot D, Fritsche E, Shafer TJ. 2010. Neural progenitor cells as models for high throughput screens of developmental neurotoxicity: state of the science. Neurotoxicol. Teratol. 32: 4-15.
24. Bremer S, Hartung T. 2004.The use of embryonic stem cells for regulatory developmental toxicity testing in vitro-the current status of test development. Curr. Pharm. Des. 22: 2733-2747.
25. Brott D, Gould S, Jones H, Schofield J, Prior H, Valentin JP, Bjurstrom S, Kenne K, Schuppe-Koistinen I, Katein A, Foster-Brown L, Betton G, Richardson R, Evans G, Louden C. 2005. Biomarkers of drug-induced vascular injury. Toxicol. Appl. Pharmacol. 207: S441-S445.
26. Bugelski PJ, Atif U, Molton S, Toeg I, Lord PG, Morgan DG. 2000. A strategy for primary high throughput cytotoxicity testing in pharmaceutical toxicology. Pharmacol. Res. 17: 1265-1272.
27. Bulera SJ, Eddy SM, Ferguson E, Jatkoe TA, Reindel JF, Bleavins MR, De La Iglesia FA. 2001. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 33: 1239-1258.
28. Car BD, Robertson RT. 1999. Commentary: discovery toxicology- a nascent science. Toxicol. Pathol. 27: 481-483.
29. Cavero I. 2009. Exploratory Safety Pharmacology a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Expert Opin. Drug Saf. 8: 627-647.
30. Chan K, Truong D, Shangari N, O'Brien PJ. 2005. Drug-induced mitochondrial toxicity. Expert Opin. Drug Metab. Toxicol. 1: 655-669.
31. Chapman KL, Holzgrefe H, Black LE, Brown M, Chellman G, Copeman C, Couch J, Creton S, Gehen S, Hoberman A, Kinter LB, Madden S, Mattis C, Stemple HA, Wilson S. 2013. Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation. Regul. Toxicol. Pharmacol. 66: 88-103.
32. Chaudhari GH, Chennubhotla KS, Chatti K, Kulkarni P. 2013. Optimization of the adult zebrafish ECG method for assessment of drug-induced QTc prolongation. J. Pharmacol. Toxicol. Methods 67: 115-120.
33. Chen JN, Fishman MC. 1996. Zebrafish tinman homolog demarcates the heart field and initiates myocardial differentiation. Development 122: 3809-3816.
34. Chiu LL, Cunningham LL, Raible DW, Rubel EW, Ou HC. 2008. Using the zebrafish lateral line to screen for ototoxicity. J. Assoc. Res. Otolaryngol. 9: 178-190.
35. Clarke CJ, Haselden JN. 2008. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol. 36: 140-147.
36. Cohen JD, Babiarz JE, Abrams RM, Guo L, Kameoka S, Chiao E, Taunton J, Kolaja KL. 2011. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 257: 74-83.
37. Comley RA, Kallend D. 2013. Imaging in the cardiovascular and metabolic disease area. Drug Discov. Today 18: 185-192.
38. Coyne L, Shan M, Przyborski SA, Hirakawa R, Halliwell RF. 2011. Neuropharmacological properties of neurons derived from human stem cells. Neurochem. Int. 59: 404-412.
39. CPMP. 1997. Replacement of Animal Studies by in vitro Models. CPMP/SWP/728/95.
40. Crawford M. 2010. State of the Industry 2010. News Magazine, April; 34-39.
41. Custer LL, Sweder KS. 2008. The role of genetic toxicology in drug discovery and optimization. Curr. Drug Metab. 9: 978-985.
42. Dalgetty DM, Medine CN, Iredale JP, Hay DC. 2009. Progress and future challenges in stem cell-derived liver technologies. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G241-248.
43. Dalmas DA, Scicchitano MS, Mullins D, Hughes-Earle A, Tatsuoka K, Magid-Slav M, Frazier KS, Thomas HC. 2011. Potential candidate genomic biomarkers of drug induced vascular injury in the rat. Toxicol. Appl. Pharmacol. 257: 284-300.
44. Dambach DM, Andrews BA, Moulin F. 2005. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33: 17-26.
45. Dara L, Ji C, Kaplowitz N. 2011. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology 53: 1752-1763.
46. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W. 2010. Renal biomarker qualification submission a dialog between the FDA-EMEA and predictive safety testing consortium. Nat. Biotechnol. 28: 455-462.
47. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22: 151-185.
48. Ding YJ, Chen YH. 2012. Developmental nephrotoxicity of aristolochic acid in a zebrafish model. Toxicol. Appl. Pharmacol. 261: 59-65.
49. Dorsky RI, Sheldahl LC, Moon RT. 2002. A transgenic Lef1/beta-catenin-dependent reporter is expressed in spatially restricted domains throughout zebrafish development. Dev. Biol. 241: 229-237.
50. Dykens JA, Marroquin LD, Will Y. 2007. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7: 161-175.
51. Dykens JA, Will Y. 2007. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12: 777-785.
52. Egan WJ, Zlokarnik G, Grootenhuis PDJ. 2004. In silico prediction of drug safety: despite progress there is abundant room for improvement. DDT 1: 381-386.
53. Ellis JK, Athersuch TJ, Cavill R, Radford R, Slattery C, Jennings P, McMorrow T, Ryan MP, Ebbels TM, Keun HC. 2011. Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system. Mol. Biosyst. 7: 247-257.
54. EMEA. 2008. Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. Doc. Ref. EMEA/679719/2008 Rev. 1 [accessed on 7 June 2013].
55. EMEA. 2010. Reflection paper on non-clinical evaluation of drug-induced liver injury (DILI). EMEA/CHMP/SWP/150115/2006.
56. Evans SM, Casartelli A, Herreros E, Minnick DT, Day C, George E, Westmoreland C. 2001. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol. In Vitro 15:579-584.
57. Fabre N, Anglade I, Vericat JA. 2009. Application of toxicogenomic tools in the drug research and development process. Toxicol. Lett. 186: 13-17.
58. Fennell M, Chan H, Wood A. 2006. Multiparameter measurement of caspase 3 activation and apoptotic cell death in NT2 neuronal precursor cells using high-content analysis. J. Biomol. Screen. 11: 296-302.
59. Fiehn O. 2002. Metabolomics-The link between genotypes and phenotypes. Plant Mol. Biol. 48: 155-171.
60. Fielden MR, Kolaja KL. 2008. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin. Drug Saf. 7: 107-110.
61. Fromenty B, Pessayre D. 1995. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67: 101-154.
62. Fung M, Thornton A, Mybeck K, Hsiao-hui Wu J, Hornbuckle K, Muniz E. 2001. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960-1999. Drug Inf. J. 35: 293-317.
63. Gao J, Garulacan LA, Storm SM, Hefta SA, Opiteck GJ, Lin JH, Moulin F, Dambach DM. 2004. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol. In Vitro 18: 533-541.
64. Gao J, Garulacan LA, Storm SM, Opiteck GJ, Dubaquie Y, Hefta SA, Dambach DM, Dongre AR. 2005. Biomarker discovery in biological fluids. Methods 35: 291-302.
65. Gasparri F, Cappella P, Galvani A. 2006. Multiparametric cell cycle analysis by automated microscopy. J. Biomol. Screen. 11: 586-598.
66. Gasparri F, Mariani M, Sola F, Galvani A. 2004. Quantification of the proliferation index of human dermal fibroblast cultures with the Array Scan high-content screening reader. J. Biomol. Screen. 9: 232-234.
67. Genschow E, Spielmann H, Scholz G, Pohl I, Seiler A, Clemann N, Bremer S, Becker K. 2004. Validation of the embryonic stem cell test (EST) in the international ECVAM validation study of three in vitro embryotoxicity tests. ATLA 32: 209-244.
68. Genschow E, Spielmann H, Scholz G, Seiler A, Brown N, Piersma A, Brady M, Clemann N, Huuskonen H, Paillard F, Bremer S, Becker K. 2002. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the validation of alternative methods. ATLA 30: 151-176.
69. Gerets HH, Hanon E, Cornet M, Dhalluin S, Depelchin O, Canning M, Atienzar FA. 2009. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: A preliminary study using a multiplexing approach. Toxicol. In Vitro 23: 319-332.
70. Gintant G. 2011. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol. Ther. 129: 109-119.
71. Gómez-Lechón MJ, Lahoz A, Gombau L, Castell JV, Donato MT. 2010. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 16: 1963-1977.
72. Goodsaid F, Frueh F. 2007. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 9: E105-E108.
73. Goodsaid FM. 2004. Identification and measurement of genomic biomarkers of nephrotoxicity. J. Pharmacol. Toxicol. Methods 49: 183-186.
74. Granato M, Nüsslein-Volhard C. 1996. Fishing for genes controlling development. Curr. Opin. Gen. Dev. 6: 461-468.
75. Greene N, Aleo MD, Louise-May S, Price DA, Will Y. 2010.Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorg. Med. Chem. Lett. 20: 5308-5312.
76. Greenhough S, Medine CN, Hay DC. 2010. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology 278: 250-255.
77. Greer ML, Barber J, Eakins J, Kenna JG. 2009. Mechanisms of drug hepatotoxicity in man: novel insights provided by the THLE-CYP cell panel. Toxicology 262: 4-14.
78. Guguen-Guillouzo C, Corlu A, Guillouzo A. 2010. Stem-cell derived hepatocytes and their use in toxicology. Toxicology 270: 3-9.
79. Gum RJ, Hickman D, Fagerland JA, Heindel MA, Gagne GD, Schmidt JM, Michaelides MR, Davidsen SK, Ulrich RG. 2001. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 62: 1661-1673.
80. Gustafson AL, Stedman DB, Ball J, Hillegass JM, Flood A, Zhang CX, Panzica-Kelly J, Cao J, Coburn A, Enright BP, Tornesi MB, Hetheridge M, Augustine-Rauch KA. 2012. Inter-laboratory assessment of a harmonized zebrafish developmental toxicology assay - Progress report on phase I. Reprod. Toxicol. 33: 155-164.
81. Guth BD, Germeyer S, Kolb W, Markert M. 2004. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J. Pharmacol. Toxicol. Methods 49: 159-169.
82. Haab BB. 2001. Advances in protein microarray technology for protein expression and interaction profiling. Curr. Opinion Drug Discov. Develop. 4: 116-123.
83. Halliwell WH. 1997. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 25: 53-60.
84. Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, Atkinson J, Ayala M, Box H, Cross M, Delaunois A, Dermody A, Govindappa K, Guillon JM, Jenkins R, Kenna G, Lemmer B, Meecham K, Olayanju A, Pestel S, Rothfuss A, Sidaway J, Sison-Young R, Smith E, Stebbings R, Tingle Y, Valentin JP, Williams A, Williams D, Park K, Goldring C. 2013. Safety pharmacology - Current and emerging concepts. Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2013.04.039.
85. He JH, Guo SY, Zhu F, Zhu JJ, Chen YX, Huang CJ, Gao JM, Dong QX, Xuan YX, Li CQ. 2013. A zebrafish phenotypic assay for assessing drug-induced hepatotoxicity. J. Pharmacol. Toxicol. Methods 67: 25-32.
86. Herlich JA, Taggart P, Proctor J, Stahle P, Colis R, Hall L, Pugsley MK. 2009. The Non-GLP toleration/Dose Range Finding study: design and methodology used in an early toxicology screening program. Proc. West. Pharmacol. Soc. 52: 94-98.
87. Hettwer M, Reis-Fernandes MA, Iken M, Ott M, Steinberg P, Nau H. 2010. Metabolic activation capacity by primary hepatocytes expands the applicability of the embryonic stem cell test as alternative to experimental animal testing. Reprod. Toxicol. 30: 113-120.
88. Higgins J, Cartwright ME, Templeton AC. 2012. Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure. Drug Discov. Today 17: 828-836.
89. Hill AJ, Teraoka H, Heideman W, Peterson RE. 2005. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol. Sci. 86: 6-19.
90. Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, Mally A. 2010. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 277: 49-58.
91. Holmes E, Nicholson JK, Tranter G. 2001. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. Chem. Res. Toxicol. 14: 182-191.
92. Hook LA. 2012. Stem cell technology for drug discovery and development. Drug Discov. Today 17: 336-342.
93. Houck KA, Kavlock RJ. 2008. Understanding mechanisms of toxicity: Insights from drug discovery research. Toxicol. Appl. Pharmacol. 277: 163-178.
94. Hrach J, Mueller SO, Hewitt P. 2011. Development of an in vitro liver toxicity prediction model based on longer term primary rat hepatocyte culture. Toxicol. Lett. 206: 189-196.
95. Hruban Z. 1984. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 55: 53-76.
96. Huang Q, Dunn RT, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, Blanchard KT. 2001. Assessment of cisplatin-induced nephrotoxicity by gene array technology. Toxicol. Sci. 60: 214.
97. Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y. 2008. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18: 4872-4875.
98. Hynes J, Marroquin LD, Ogurtsov VI, Christiansen KN, Stevens GJ, Papkovsky DB, Will Y. 2006. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol. Sci. 92: 186-200.
99. Hynes J, Nadanaciva S, Swiss R, Carey C, Kirwan S, Will Y. 2013. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol. In Vitro 27: 560-569.
100. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
101. Ivanov MA, Heuillet E, Vintezou P, Melcion C, Cordier A. 1992. Primary culture of hepatocytes in the investigation of drug induced steatosis. In In Vitro Methods in Toxicology, Jolles G, Cordier A (eds). Academic Press: New York; 165-187.
102. Jacobs A. 2009. An FDA perspective on the nonclinical use of the X-omics technologies and the safety of new drugs. Toxicol. Lett. 186: 32-35.
103. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. 2002. Mechanisms of hepatotoxicity. Toxicol. Sci. 65: 166-176.
104. John-Baptiste A, Vitsky A, Sace F, Zong Q, Ko M, Yafawi R, Liu L. 2012. Comparison of 3 kidney injury multiplex panels in rats. Int. J. Toxicol. 31: 529-536.
105. Johnson DE, Wolfgang GHI. 2001. Assessing the potential toxicity of new Pharmaceuticals. Curr. Top. Med. Chem. 1: 233-245.
106. Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. 2010. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol. Interv. 10: 98-111.
107. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6: 161-225.
108. Kalgutkar AS, Soglia JR. 2005. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 1: 91-142.
109. Kerns W, Schwartz L, Blanchard K, Burchiel S, Essayan D, Fung E, Johnson R, Lawton M, Louden C, MacGregor J, Miller F, Nagarkatti P, Robertson D, Snyder P, Thomas H, Wagner B, Ward A, Zhang J. 2005. Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203: 62-87.
110. Kim JH, Scialli AR. 2011. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122: 1-6.
111. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. 1995. Stages of embryonic development of the zebrafish. Dev. Dyn. 203: 253-310.
112. Kis E, Ioja E, Rajnai Z, Jani M, Méhn D, Herédi-Szabó K, Krajcsi P. 2012. BSEP inhibition - In vitro screens to assess cholestatic potential of drugs. Toxicol. In Vitro 26: 1294-1299.
113. Kiyosawa N, Manabe S, Yamoto T, Sanbuissho A. 2010. Practical application of toxicogenomics for profiling toxicant-induced biological perturbations. Int. J. Mol. Sci. 11: 3397-3412.
114. Kleinstreuer NC, Smith AM, West PR, Conard KR, Fontaine BR, Weir-Hauptman AM, Palmer JA, Knudsen TB, Dix DJ, Donley EL, Cezar GG. 2011. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 257: 111-121.
115. Kokel D, Bryan J, Laggner C, White R, Cheung CY, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ, Macrae CA, Shoichet B, Peterson RT. 2010. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol. 6: 231-237.
116. Koslov-Davino E, Wang X, Schroeter T. 2013. Target promiscuity and physicochemical properties contribute to pharmacologically induced ER-stress. Toxicol. In Vitro 27: 204-210.
117. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, Naughton B, Roth A. 2013. A Long-Term three dimensional liver Co-Culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268: 1-16.
118. Kramer JA, Sagartz JE, Morris DL. 2007. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6: 636-649.
119. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, Migeon JC. 2003. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Dev. 6: 470.
120. Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, Vojnits K, Baquié M, Waldmann T, Ensenat-Waser R, Jagtap S, Evans RM, Julien S, Peterson H, Zagoura D, Kadereit S, Gerhard D, Sotiriadou I, Heke M, Natarajan K, Henry M, Winkler J, Marchan R, Stoppini L, Bosgra S, Westerhout J, Verwei M, Vilo J, Kortenkamp A, Hescheler J, Hothorn L, Bremer S, van Thriel C, Krause KH, Hengstler JG, Rahnenführer J, Leist M, Sachinidis A. 2013. Human embryonic stem cell-derived test systems for developmental neurotoxicity a transcriptomics approach. Arch. Toxicol. 87: 123-143.
121. Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. 2007. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv. Drug Deliv. Rev. 59: 43-55.
122. Kuegler PB, Zimmer B, Waldmann T, Baudis B, Ilmjärv S, Hescheler J, Gaughwin P, Brundin P, Mundy W, Bal-Price AK, Schrattenholz A, Krause KH, van Thriel C, Rao MS, Kadereit S, Leist M. 2010. Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. ALTEX 27: 17-42.
123. Kullak-Ublick GA, Stieger B, Meier PJ. 2004. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342.
124. Langheinrich U, Vacun G, Wagner T. 2003. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 193: 370-382.
125. Lazzari G, Tessaro I, Crotti G, Galli C, Hoffmann S, Bremer S, Pellizzer C. 2008. Development of an in vitro test battery for assessing chemical effects on bovine germ cells under the ReProTect umbrella. Toxicol. Appl. Pharmacol. 233: 360-370.
126. Lee WM. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349: 474-485.
127. Leeson PD, Springthrope B. 2007.The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6: 881-890.
128. Leishman DJ, Beck TW, Dybdal N, Gallacher DJ, Guth BD, Holbrook M, Roche B, Wallis RM. 2012. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society. J. Pharmacol. Toxicol. Methods 65: 93-101.
129. Lienemann K, Plötz T, Pestel S. 2008. NMR-based urine analysis in rats: prediction of proximal tubule kidney toxicity and phospholipidosis. J. Pharmacol. Toxicol. Methods 58: 41-49.
130. Loget OML. 2008. Non-clinical safety in drug development. Bull. Acad. Vet. France 161(1): 61-69 URL academieveterinaire.free.fr/bulletin/pdf/2008/numero01/61.pdf [accessed on 25 March 2013].
131. Lorenzetti S, Marcoccia D, Narciso L, Mantovani A. 2010. Cell viability and PSA secretion assays in LNCaP cells: A tiered in vitro approach to screen chemicals with a prostate-mediated effect on male reproduction within the ReProTect project. Reprod. Toxicol. 30: 25-35.
132. Louden C, Brott D, Katein A, Kelly T, Gould S, Jones H, Betton G, Valetin JP, Richardson RJ. 2006. Biomarkers and mechanisms of drug-induced vascular injury in non-rodents. Toxicol. Pathol. 34: 19-26.
133. Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K. 2011. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods 63: 59-68.
134. Luciano AM, Franciosi F, Lodde V, Corbani D, Lazzari G, Crotti G, Galli C, Pellizzer C, Bremer S, Weimer M, Modina SC. 2010. Transferability and inter-laboratory variability assessment of the in vitro bovine oocyte maturation (IVM) test within ReProTect. Reprod. Toxicol. 30: 81-88.
135. Luft J, Bode G. 2002. Integration of safety pharmacology endpoints into toxicology studies. Fundam. Clin. Pharmacol. 16: 91-103.
136. st century a view from the Pharmaceutical industry. Toxicol. Sci. 110: 40-46.
137. Mandenius CF, Andersson TB, Alves PM, Batzl-Hartmann C, Björquist P, Carrondo MJ, Chesne C, Coecke S, Edsbagge J, Fredriksson JM, Gerlach JC, Heinzle E, Ingelman-Sundberg M, Johansson I, Küppers-Munther B, Müller-Vieira U, Noor F, Zeilinger K. 2011. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. ATLA 39: 147-171.
138. Mannargudi B, McNally D, Reynolds W, Uetrecht J. 2009. Bioactivation of minocycline to reactive intermediates by myeloperoxidase, horseradish peroxidase, and hepatic microsomes: implications for minocycline-induced lupus and hepatitis. Drug Metab. Dispos. 37: 1806-1818.
139. Marrer E, Dieterle F. 2010. Impact of biomarker development on drug safety assessment. Toxicol. Appl. Pharmacol. 243: 167-179.
140. Matsuzawa T, Hashimoto M, Nara H, Yoshida M, Tamura S, Igarashi T. 1997. Current status of conducting function tests in repeated dose toxicity studies in Japan. J. Toxicol. Sci. 22: 375-382.
141. Matthews PM, Rabiner EA, Passchier J, Gunn RN. 2012. Technologies: preclinical imaging for drug development. Drug Discov. Today http://dx.doi.org/10.1016/j.ddtec. 2012.04.004 DOI: 10.1016/j.ddtec.%202012.04.004.
142. Matthews PM, Rabiner I, Gunn R. 2011. Non-invasive imaging in experimental medicine for drug development. Curr. Opin. Pharmacol. 11: 501-507.
143. May JE, Morse HR, Xu J, Donaldson C. 2012. Development of a novel, physiologically relevant cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells. Toxicol. Appl. Pharmacol. 263: 374-389.
144. McGrath P, Li CQ. 2008. Zebrafish a predictive model for assessing drug-induced toxicity. Drug Discov. Today 13: 394-401.
145. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, Johnson MD. 2001. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitro Mol. Toxicol. 14: 177-190.
146. Meamer R, Karamali F, Sadeghi HM, Etebari M, Nasr-Esfahani MH, Baharvand H. 2010. Toxicity of ecstasy (MDMA) towards embryonic stem-cell derived cardiac and neural cells. Toxicol. In Vitro 24: 1133-1138.
147. Melis M, de Swart J, de Visser M, Berndsen SC, Koelewijn S, Valkema R, Boerman OC, Krenning EP, de Jong M. 2010. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy. J. Nucl. Med. 51: 1962-1968.
148. Merrick BA, Witzmann FA. 2009. The role of toxicoproteomics in assessing organ specific toxicity. EXS 99: 367-400.
149. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. 2003. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107: 1355-1358.
150. Mingoia RT, Nabb DL, Yang CH, Han X. 2007. Primary culture of rat hepatocytes in 96 well plates: Effects of extracellular matrix configuration on cytochrome P450 enzyme activity and inducibility, and its application in in vitro cytotoxicity screening. Toxicol. In Vitro 21: 165-173.
151. Minowa Y, Kondo C, Uehara T, Morikawa Y, Okuno Y, Nakatsu N, Ono A, Maruyama T, Kato I, Yamate J, Yamada H, Ohno Y, Urushidani T. 2012. Toxicogenomic multigene biomarker for predicting the future onset of proximal tubular injury in rats. Toxicology 297: 47-56.
152. Miret S, De Groene EM, Klaffke W. 2006. Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J. Biomol. Screen. 11: 184-193.
153. Mittelstadt SW, Hemenway CL, Craig MP, Hove JR. 2008. Evaluation of zebrafish embryos as a model for assessing inhibition of hERG. J. Pharmacol. Toxicol. Methods 57: 100-105.
154. Moser VC. 2011. Functional assays for neurotoxicity testing. Toxicol. Pathol. 39: 36-45.
155. Muster W, Breidenbach A, Fischer H, Kirchner S, Muller L, Pahler A. 2008. Computational toxicology in drug development. DDT 13: 303-310.
156. Muth-Köhne E, Wichmann A, Delov V, Fenske M. 2012. The classification of motor neuron defects in the zebrafish embryo toxicity test (ZFET) as an animal alternative approach to assess developmental neurotoxicity. Neurotoxicol. Teratol. 34: 413-424.
157. Myllynen P, Mathiesen L, Weimer M, Annola K, Immonen E, Karttunen V, Kummu M, Mørck TJ, Nielsen JK, Knudsen LE, Vähäkangas K. 2010. Preliminary interlaboratory comparison of the ex vivo dual human placental perfusion system. Reprod. Toxicol. 30: 94-102.
158. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y. 2007a. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol. In Vitro 21: 902-911.
159. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. 2007b. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 223: 277-287.
160. Natalie M, Margino S, Erik H, Geert RV, Freddy VG, Jaques VG. 2010. Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. In Vitro 24: 1417-1425.
161. Nicholson JK, Lindon JC, Holmes E. 1999. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
162. O'Brien PJ, et al. 2003. Predicting drug-induced human hepatotoxicity with in vitro cytotoxicity assays. In Proceedings Tox '03. London, UK.
163. O'Brien PJ, Chan K, Silber PM. 2004. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem. Biol. Interact. 150: 97-114.
164. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter CM, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C. 2006. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80: 580-604.
165. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32: 56-67.
166. Olson H, Betton G, Stritar J, Robinson D. 1998. The predictivity of the toxicity of pharmaceuticals in humans from animal data-an interim assessment. Toxicol. Lett. 102-103: 535-538.
167. Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, Jin H, Yu Y, Muniappa N, Forest T, Clouse HK, Reynolds S, Bailey WJ, Thudium DT, Topper MJ, Skopek TR, Sina JF, Glaab WE, Vonderscher J, Maurer G, Chibout SD, Sistare FD, Gerhold DL. 2010. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat. Biotechnol. 28: 486-494.
168. Park MJ, Lee KR, Shin DS, Chun HS, Kim CH, Ahn SH, Bae MA. 2013. Predicted drug-induced bradycardia related cardiotoxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests. Toxicol. Lett. 216: 9-15.
169. Parkinson J, Visser SA, Jarvis P, Pollard C, Valentin JP, Yates JW, Ewart L. 2013. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. DOI: 10.1016/j.vascn.2013.03.007.
170. Pauli-Magnus C, Meier PJ. 2006. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44: 778-787.
171. Perz-Edwards A, Hardison NL, Linney E. 2001. Retinoic acid-mediated gene expression in transgenic reporter zebrafish. Dev. Biol. 229: 89-101.
172. Pessayre D, Mansouri A, Berson A, Fromenty B. 2010. Mitochondrial involvement in drug-induced liver injury. Handb. Exp. Pharmacol. 196: 311-365.
173. Pessayre D, Mansouri A, Haouzi D, Fromenty B. 1999. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 15: 367-373.
174. Phillips GW, Irwin WA, Howard-Cofield EJ, Randle LE, Abraham VC, Haskins JR, O'Brien PJ. 2005. Incorporation of an oxidative stress biomarker into high content screening (HCS) for human toxicity potential. 11th Annual Meeting of the Society for Biomol. Screen. (SBS), P05020.
175. Pohjala L, Tammela P, Samanta SK, Yli-Kauhaluoma J, Vuorela P. 2007. Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays. Anal. Biochem. 362: 221-228.
176. Pugsley MK. 2004. An overview of some pharmacological methods used in safety pharmacology studies. Proc. West. Pharmacol. Soc. 47: 18-22.
177. Rausch O. 2006. High content cellular screening. Curr. Opin. Chem. Biol. 10: 316-320.
178. Reasor MJ, Kacew S. 2001. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 226: 825-830.
179. Redfern WS, Ewart LC, Lainee P, Pinches M, Robinson S, Valentin JP. 2013. Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol Res. 2: 209-234.
180. Redfern WS, Waldron G, Winter MJ, Butler P, Holbrook M, Wallis R, Valentin JP. 2008. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring? J. Pharmacol. Toxicol. Methods 58: 110-117.
181. Reimers MJ, Hahn ME, Tanguay RL. 2004. Two zebrafish alcohol dehydrogenases share common ancestry with mammalian class I, II, IV, and V alcohol dehydrogenase genes but have distinct functional characteristics. J. Biol. Chem. 279: 38303-38312.
182. Renier C, Faraco JH, Bourgin P, Motley T, Bonaventure P, Rosa F, Mignot E. 2007. Genomic and functional conservation of sedative-hypnotic targets in the zebrafish. Pharmacogenet. Genomics 17: 237-253.
183. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. 2000. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18: 399-404.
184. Ricaurte GA, McCann UD, Szabo Z, Scheffel U. 2000. Toxicodynamics and long-term toxicity of the recreational drug 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy). Toxicol. Lett. 112-113: 143-146.
185. Richards FM, Alderton WK, Kimber GM, Liu Z, Strang I, Redfern WS, Valentin JP, Winter MJ, Hutchinson TH. 2008. Validation of the use of zebrafish larvae in visual safety assessment. J. Pharmacol. Toxicol. Methods 58: 50-58.
186. Richards GR, Smith AJ, Parry F, Platts A, Chan GK, Leveridge M, Kerby JE, Simpson PB. 2006. A morphology- and kinetics-based cascade for human neural cell high content screening. Assay Drug Dev. Technol. 4: 143-152.
187. Roberts RA, Smith RA, Safe S, Szabo C, Tjalkens RB, Robertson FM. 2010. Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology 276: 85-94.
188. Robertson GD, Reily MD, Sigler RE, Wells DF, Paterson DA, Braden TK. 2000. Metabonomics: Evaluation of nuclear magnetic resonance systems (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57: 326-337.
189. Rubinstein AL. 2006. Zebrafish assays for drug toxicity screening. Expert Opin. Drug Metab. Toxicol. 2: 231-240.
190. San RHC. 2006. Preclinical Genotoxicity Testing-Past, Present, and Future. In The process of new drug discovery and development, Smith CG, O'Donnell JT (eds). 1st edn., Informa Healthcare: USA; 305-311.
191. Sandow J. 2006. Assays in endocrine safety pharmacology. In Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Vogel GH, Hock FJ, Maas J, Mayer D (eds). Springer-Verlag: Berlin Heidelberg; 327-363.
192. Sartipy P, Björquist P. 2011. Concise review: human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment. Stem Cells 29: 744-748.
193. Sasseville VG, Lane JH, Kadambi VJ, Bouchard P, Lee FW, Balani SK, Miwa GT, Smith PF, Alden CL. 2004. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem. Biol. Interact. 150: 9-25.
194. Scanu M, Mancuso L, Cao G. 2011. Evaluation of the use of human mesenchymal stem cells for acute toxicity tests. Toxicol. In Vitro 25: 1989-1995.
195. Schenk B, Weimer M, Bremer S, van der Burg B, Cortvrindt R, Freyberger A, Lazzari G, Pellizzer C, Piersma A, Schäfer WR, Seiler A, Witters H, Schwarz M. 2010. The ReProTect Feasibility Study a novel comprehensive in vitro approach to detect reproductive toxicants. Reprod. Toxicol. 30: 200-218.
196. Seng WL, McGrath P, Li C. 2010. Zebrafish hair cell model for assessing ototoxicity. J. Pharmacol. Toxicol. Methods 62: e10.
197. Sipes NS, Padilla S, Knudsen TB. 2011. Zebrafish-as an integrative model for twenty-first century toxicity testing. Birth Defects Res. C Embryo Today 93: 256-267.
198. Snodin DJ. 2002. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Toxicol. Lett. 127: 161-168.
199. Snyder RD, Smith MD. 2005. Computational prediction of genotoxicity: room for improvement. DDT 10: 1119-1124.
200. Snykers S, De Kock J, Rogiers V, Vanhaecke T. 2009. In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art. Stem Cells 27: 577-605.
201. Spielmann H, Pohl I, Doring B, Liebsch M, Moldenhauer F. 1997. The embryonic stem cell test, an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. Toxicol. In Vitro 10: 119-127.
202. Steiner S, Witzmann FA. 2000. Proteomics: applications and opportunities in preclinical drug development. Electrophoresis 21: 2099-2104.
203. Sukardi H, Chng HT, Chan EC, Gong Z, Lam SH. 2011. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin. Drug Metab. Toxicol. 7: 579-589.
204. Suter L, Schroeder S, Meyer K, Gautier JC, Amberg A, Wendt M, Gmuender H, Mally A, Boitier E, Ellinger-Ziegelbauer H, Matheis K, Pfannkuch F. 2011. EU Framework 6 Project: Predictive Toxicology (PredTox)-overview and outcome. Toxicol. Appl. Pharmacol. 252: 73-84.
205. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
206. Tamaki C, Nagayama T, Hashiba M, Fujiyoshi M, Hizue M, Kodaira H, Nishida M, Suzuki K, Takashima Y, Ogino Y, Yasugi D, Yoneta Y, Hisada S, Ohkura T, Nakamura K. 2013. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J. Toxicol. Sci. 38: 581-598.
207. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147.
208. Tonomura Y, Matsushima S, Kashiwagi E, Fujisawa K, Takagi S, Nishimura Y, Fukushima R, Torii M, Matsubara M. 2012. Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats. Toxicology 302: 179-189.
209. Tonomura Y, Tsuchiya N, Torii M, Uehara T. 2010. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 273: 53-59.
210. Uehara T, Kiyosawa N, Shimizu T, Omura K, Hirode M, Imazawa T, Mizukawa Y, Ono A, Miyagishima T, Nagao T, Urushidani T. 2008. Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics based approach to assessing risk of toxicity to humans. Hum. Exp. Toxicol. 27: 23-35.
211. Uehara T, Kondo C, Morikawa Y, Hanafusa H, Ueda S, Minowa Y, Nakatsu N, Ono A, Maruyama T, Kato I, Yamate J, Yamada H, Ohno Y, Urushidani T. 2013. Toxicogenomic biomarkers for renal papillary injury in rats. Toxicology 303: 1-8.
212. Ulrich RG, Kilgore KS, Elena LS, Cramer CT, Ginsberg LC. 1991. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol. Methods 1: 89-105.
213. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV. 2010. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 28: 478-485.
214. Valentin JP, Hammond T. 2008. Safety and secondary pharmacology: Successes, threats, challenges and opportunities. J. Pharmacol. Toxicol. Methods 58: 77-87.
215. Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S, Martinez V, Pollard C, Redfern W, Wallis R. 2009. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 60: 152-158.
216. Valerio LG. 2012. Predictive Computational Toxicology to Support Drug Safety Assessment. Methods Mol. Biol. 930: 341-354.
217. Van Cauteren H, Lumley CE. 1997. Harmonization of international toxicity testing guidelines for pharmaceuticals. Contributions to refinement and reduction in animal use. Eur. Biomed. Res. Assoc. Bull. November: 4-9.
218. van Ravenzwaay B, Cunha GC, Leibold E, Looser R, Mellert W, Prokoudine A, Walk T, Wiemer J. 2007. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 172: 21-28.
219. Van Summeren A, Renes J, van Delft JH, Kleinjans JC, Mariman EC. 2012. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol. In Vitro 26: 373-385.
220. vanVliet E, Morath S, Eskes C, Linge J, Rappsilber J, Honegger P, Hartung T, Coecke S. 2008. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 29: 1-12.
221. Vojnits K, Bremer S. 2010. Challenges of using pluripotent stem cells for safety assessments of substances. Toxicology 270: 10-17.
222. Wadey RM, Pinches MG, Jones HB, Riccardi D, Price SA. 2012. Tissue Expression and Correlation of a Panel of Urinary Biomarkers Following Cisplatin-induced Kidney Injury. Toxicol. Pathol. 1-12. DOI: 10.1177/0192623313492044
223. Wagner JA. 2008. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48: 631-651.
224. Wang EJ, Snyder RD, Fielden MR, Smith RJ, Gu YZ. 2008. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 246: 91-100.
225. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120: 359-368.
226. Watkins SJ, Borthwick GM, Arthur HM. 2011. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell. Dev. Biol. Anim. 47: 125-131.
227. Westerfield M 1994. The zebrafish book a guide for the laboratory use of Zebrafish (Danio rerio), 2nd edn. University of Oregon Press: Eugene.
228. Wetmore BA, Merrick BA. 2004. Toxicoproteomics: Proteomics applied to Toxicology and Pathology. Toxicol. Pathol. 32: 619-642.
229. Weyermann J, Lochmann D, Zimmer A. 2005. A practical note on the use of cytotoxicity assays. Int. J. Pharm. 288: 369-376.
230. Whitebread S, Hamon J, Bojanic D, Urban L. 2005. In vitro safety pharmacology profiling: an essential tool for successful drug development. DDT 10:1421-1433.
231. Williams PD. 1990. The role of pharmacological profiling in safety assessment. Regul. Toxicol. Pharmacol. 12: 238-252.
232. Winkelmann CT, Wise LD. 2009. High-throughput micro-computed tomography imaging as a method to evaluate rat and rabbit fetal skeletal abnormalities for developmental toxicity studies. J. Pharmacol. Toxicol. Methods 59: 156-165.
233. Witters H, Freyberger A, Smits K, Vangenechten C, Lofink W, Weimer M, Bremer S, Ahr PHJ, Berckmans P. 2010. The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: Results of test performance and transferability. Reprod. Toxicol. 30: 60-72.
234. Witzmann FA, Fultz CD, Grant RA, Wright LS, Kornguth SE, Siegel FL. 1998. Differential expression of cytosolic proteins in rat kidney cortex and medulla: preliminary proteomics. Electrophoresis 19: 2491-2497.
235. Wolfgang GHI, Johnson DE. 2002. Web resources for drug toxicity. Toxicology 173: 67-74.
236. Wu Y, Connors D, Barber L, Jayachandra S, Hanumegowda UM, Adams SP. 2009. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. Toxicol. In Vitro 23: 1170-1178.
237. Xie HG, Wang SK, Cao CC, Harpur E. 2013. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacol. Ther. 137: 100-107.
238. Xu JJ, Diaz D, O'Brien PJ. 2004. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 150: 115-128.
239. Xu JJ, Diaz D, O'Brien PJ. 2008. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105: 97-105.
240. Yudate HT, Kai T, Aoki M, Minowa Y, Yamada T, Kimura T, Ono A, Yamada H, Ohno Y, Urushidani T. 2012. Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration. Toxicology 295: 1-7.